盆腔器官脱垂术后阿片类药物需求的个体化预测:一项随机对照试验
本研究在学术医疗中心对盆腔器官脱垂手术患者进行随机对照试验,比较基于预测模型的阿片类药物处方与对照处方。主要结局为术后14天剩余吗啡毫克当量(MME),预测模型组平均剩余16.8±21.1 MME,对照组平均剩余57.7±31.0 MME,组间平均治疗效应为-42.8(95%CI,-54.0至-31.7,P<.001)。两组术后2周内使用的总MME无显著差异,患者满意度无显著差异。
要点
- 预测模型组术后14天剩余阿片类药物显著少于对照组。
- 两组术后2周内使用的总MME无显著差异,疼痛管理未受影响。
- 两组患者满意度在第1周和第2周均无显著差异。
核心结论
- 盆腔器官脱垂手术后阿片类药物处方的预测模型与更少的处方量和剩余量相关,且未影响有效疼痛管理。
研究设计与样本
- 随机对照试验,在学术医疗中心纳入接受盆腔器官脱垂手术的患者,随机分为基于预测模型的阿片类药物处方组或对照处方组。
- 共随机110例患者,最终102例纳入分析:预测模型组51例,对照组51例。
- 主要结局为术后14天剩余的吗啡毫克当量(MME),7.5 MME相当于一片5 mg羟考酮。
- 事先确定每组需要51例患者以检测剩余MME的20%差异。
主要发现
- 对照组术后14天平均剩余MME为57.7±31.0,预测模型组为16.8±21.1,协方差分析平均治疗效应为-42.8(95%CI,-54.0至-31.7,P<.001)。
- 出院当日对照组处方量显著更多,平均治疗效应为-56.5(95%CI,-65.5至47.5,P<.001)。
- 术后前2周两组总MME使用量无显著差异,平均治疗效应为-2.3(95%CI,-13.4至8.7,P=.68)。
- 第1周或第2周平均患者满意度无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether a previously developed predictive model for postoperative opioid prescription reduces opioid utilization without increasing the risk of undertreatment of pain after surgery for pelvic organ prolapse (POP). METHODS: This was a randomized controlled trial of patients undergoing surgery for POP at an academic medical center. Patients were randomized to an opioid prescription based on the predictive model or a control opioid prescription. The primary outcome was morphine milligram equivalents (MMEs) remaining after 14 days, with 7.5 MMEs equating to one tablet of 5 mg oxycodone. Secondary outcomes included MMEs prescribed, MMEs used, and patient satisfaction. Group differences in average outcomes were estimated with analysis of covariance (ANCOVA). It was determined a priori that 51 patients in each group were required to see a 20% difference in MMEs remaining. RESULTS: Between January 2023 and January 2024, 110 patients were randomized, and ultimately 102 were included in the analysis: 51 patients in the predictive model group and 51 in the control group. The control group had a significantly higher average amount of opioids remaining at 14 days after surgery (mean±SD MMEs remaining 57.7±31.0) relative to the predictive model group (mean MME±SD remaining 16.8±21.1), with an average treatment effect from ANCOVA of -42.8 (95% CI, -54.0 to -31.7, P <.001). The control group was prescribed significantly more on the day of discharge (average treatment effect -56.5, 95% CI, -65.5 to 47.5, P <.001), but the two groups did not differ significantly in the total MMEs used over the first 2 weeks after surgery (average treatment effect -2.3, 95% CI, -13.4 to 8.7, P =.68). There was no significant difference in average patient satisfaction at week 1 or 2. CONCLUSION: A predictive model for opioid prescribing after POP surgery was associated with fewer prescribed and leftover opioids without compromising effective pain management. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT05571072.
引用
- Bauer HH, Schlussel MA, Hoffberg EA, et al. Personalized Prediction of Opioid Demand After Surgery for Pelvic Organ Prolapse: A Randomized Controlled Trial. Obstet Gynecol. 2025. PMID: 40570353. doi:10.1097/AOG.0000000000005969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。